COMMUNIQUÉS West-GlobeNewswire

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
12/06/2025
Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech [...]
Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities
12/06/2025
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through [...]
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
12/06/2025
Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc [...]
Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative
12/06/2025
GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused [...]
Fortrea Adopts Limited-Duration Stockholder Rights Plan
12/06/2025
Board Committed to Protecting Long-Term Value for All Stockholders DURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today [...]
RadioMedix Debuts Proprietary bench top ²¹²Pb Generator to Support Targeted Alpha Therapy Development
12/06/2025
New bench top ²¹²Pb generator to expand clinical-grade isotope supply for targeted alpha therapy research and development HOUSTON, June 12, 2025 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology [...]
Sharecare introduces new interactive solutions to elevate health literacy and increase condition-specific treatment adherence
12/06/2025
Utilizing augmented reality, artificial intelligence, and time-based visualization, Sharecare’s newest innovative tools help life sciences brands engage, educate, and activate patients ATLANTA, June 12, 2025 (GLOBE [...]
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements
12/06/2025
1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical [...]
MedRisk Welcomes Satish Narayanan as Chief Data Officer, Expanding Data and AI Capabilities
12/06/2025
KING OF PRUSSIA, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- MedRisk, a leading managed care organization focused on improving recovery and cost outcomes in casualty claims, announced today the appointment of Satish [...]
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
12/06/2025
Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, a common and [...]
AB Science annonce la délivrance d’un brevet canadien protégeant la composition de matière d’AB8939, y compris son utilisation dans le traitement de la leucémie myéloide aigue, avec une protection jusqu’à 2036
12/06/2025
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE LA DÉLIVRANCE D'UN BREVET CANADIEN PROTÉGEANT LA COMPOSITION DE MATIERE D’AB8939, Y COMPRIS SON UTILISATION DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË (LMA), AVEC UNE [...]
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
12/06/2025
PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT PROTECTING THE COMPOSITION OF MATTER OF AB8939, INCLUDING ITS USE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML), WITH PROTECTION UNTIL 2036 THIS PATENT [...]
Diagonal Therapeutics to Present New Preclinical Data Demonstrating Disease-Modifying Potential of Receptor Clustering Antibody Approach in HHT at EHA 2025 Congress
12/06/2025
Results demonstrate potential of Company’s clustering antibody approach to address key challenges in HHT disease manifestations: restoring ALK1-mediated cellular signaling, preventing and reversing arteriovenous [...]
SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological Cancer
12/06/2025
COPENHAGEN, Denmark, June 12, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, today announced that [...]
Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children
12/06/2025
First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a [...]
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
12/06/2025
In the Phase IIIB APPULSE-PNH study, adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched to Fabhalta experienced clinically meaningful improvements in hemoglobin (Hb) levels of 2.01 g/dL on [...]
Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison
12/06/2025
Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus [...]
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
12/06/2025
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports [...]
Clariane finalise le plan de renforcement de sa structure financière avec la cession son réseau d’aide à domicile Petits-fils
12/06/2025
Communiqué de presse Clariane finalise le plan de renforcement de sa structure financière avec la cession de son réseau d’aide à domicile Petits-fils Paris, le 12 juin 2025 – Clariane (CLARI.PA – ISIN FR0010386334), [...]

Pages